Literature DB >> 3752576

Clinically significant muscle weakness induced by oral dantrolene sodium prophylaxis for malignant hyperthermia.

C B Watson, N Reierson, E A Norfleet.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3752576

Source DB:  PubMed          Journal:  Anesthesiology        ISSN： 0003-3022            Impact factor:   7.892


× No keyword cloud information.
  6 in total

Review 1.  Spasticity and drug therapy.

Authors:  E W Wuis
Journal:  Pharm Weekbl Sci       Date:  1987-10-16

2.  Complications associated with the administration of dantrolene 1987 to 2006: a report from the North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States.

Authors:  Barbara W Brandom; Marilyn Green Larach; Min-Shue Alvin Chen; Michael C Young
Journal:  Anesth Analg       Date:  2011-03-03       Impact factor: 5.108

Review 3.  Malignant hyperthermia.

Authors:  R Ben Abraham; P Adnet; V Glauber; A Perel
Journal:  Postgrad Med J       Date:  1998-01       Impact factor: 2.401

4.  Dantrolene reduces the threshold and gain for shivering.

Authors:  Chun-Ming Lin; Sharma Neeru; Anthony G Doufas; Edwin Liem; Yunus Muneer Shah; Anupama Wadhwa; Rainer Lenhardt; Andrew Bjorksten; Akiko Taguchi; Barhara Kabon; Daniel I Sessler; Andrea Kurz
Journal:  Anesth Analg       Date:  2004-05       Impact factor: 5.108

5.  Anterior mediastinal mass in a patient susceptible to malignant hyperthermia.

Authors:  G C Allen; L J Byford; F M Shamji
Journal:  Can J Anaesth       Date:  1993-01       Impact factor: 5.063

6.  The effect of long-term oral dantrolene on the neuromuscular action of rocuronium: a case report.

Authors:  Jinwoo Jeon; Sejin Song; Mun-Cheol Kim; Kye-Min Kim; Sangseok Lee
Journal:  Korean J Anesthesiol       Date:  2014-02-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.